Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer?

Expert Review of Anticancer Therapy

Volumn 14, Issue 10, 2014, Pages 1173-1187

  Rolfo, Christian ^a   Sortino, Giovanni ^b   Smits, Evelien ^a   Passiglia, Francesco ^a,b   Bronte, Giuseppe ^b   Castiglia, Marta ^a,b   Russo, Antonio ^b   Santos, Edgardo S ^c   Janssens, Annelies ^a   Pauwels, Patrick ^a   Raez, Luis ^d  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF PALERMO   (Italy)

^c BOCA RATON REGIONAL HOSPITAL   (United States)

^d Memorial Health Care System   (United States)

Author keywords

belagenpumatucel L; CIMAvax; GVAX; immunotherapy; ipilimumab; MAGE A3; non small cell lung cancer; PD 1; PD L1; racotumomab; tecemotide; TG4010; vaccines

Indexed keywords

AGATOLIMOD; BELAGENPUMATUCEL L; BEVACIZUMAB; BMS 936559; CANCER VACCINE; CARBOPLATIN; CARBOPLATIN PLUS PACLITAXEL; CIMAVAX VACCINE; CISPLATIN; CISPLATIN PLUS GEMCITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; MELANOMA ANTIGEN 3; MPDL 3280A; NAVELBINE; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PLACEBO; RACOTUMOMAB; TALACTOFERRIN; TECEMOTIDE; TG 4010; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ALLERGIC RASH; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GMCSF GENE; HUMAN; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INJECTION SITE REACTION; METASTASIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SKIN MANIFESTATION; TREATMENT OUTCOME; TUMOR ESCAPE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; NEOPLASM STAGING;

EID: 84907541018     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.952287     Document Type: Review

References (113)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12):2893-917
2. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83(5):584-94
3. Ma PC. Personalized targeted therapy in advanced non-small cell lung cancer. Cleve Clin J Med 2012;79(Electronic Suppl 1): ES56-60
4. Robert C, Schadendorf D, Messina M, MDX010-20 investigators. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013; 19(8):2232-9
5. Kantoff PW, Higano CS, Shore ND, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5): 411-22
6. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60
7. O'Sullivan T, Saddawi-Konefka R, Vermi W, et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 2012; 209(10):1869-82
8. Finn OJ. Cancer immunology. N Engl J Med 2008;358(25):2704-15
9. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117(5): 1137-46
10. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273
11. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004;172(12):7335-40
12. Gancz D, Fishelson Z. Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. Mol Immunol 2009;46(14):2794-800
13. Igney FH, Krammer PH. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 2002;71(6): 907-20
14. Nagata S. Fas ligand and immune evasion. Nat Med 1996;2(12):1306-7
15. Schimmer AD. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res 2004;64(20): 7183-90
16. Brichard VG, Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: Towards a new therapy for minimal residual disease. Expert Opin Biol Ther 2008;8(7):951-68
17. Dy GK, Adjei AA. Emerging therapeutic targets in non-small cell lung cancer. Proc Am Thorac Soc 2009;6(2):218-23
18. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-Term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26(27):4410-17
19. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94(2):275-80
20. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107(12):2866-72
21. Grunwald C, Koslowski M, Arsiray T, et al. Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. Int J Cancer 2006;118(10): 2522-8
22. Echchakir H, Mami-Chouaib F, Vergnon I, et al. A point mutation in the alpha-Actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001;61(10):4078-83
23. Takenoyama M, Baurain JF, Yasuda M, et al. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 2006;118(8):1992-7
24. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-Tissue sections with validation in small specimens. Mod Pathol 2011;24(10):1348-59
25. Bolli M, Kocher T, Adamina M, et al. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-Associated antigen expression: Potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 2002;236(6):785-93.discussion 793
26. Kim J-H, Zo JI, Nakayama H, et al. Patient and tumor characteristics impacting on MAGE-A3 expression: Screening data from the MAGRIT Phase III trial, 2011. World Congress of Lung Cancer; 3-7 July 2011. Amsterdam, Netherlands. Session MO21
27. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5(4):263-74
28. Decoster L, Wauters I, Vansteenkiste JF. Vaccination therapy for non-small-cell lung cancer: Review of agents in phase III development. Ann Oncol 2012;23(6): 1387-93
29. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24(29):4721-30
30. Fakhrai H, Tong A, Nemunaitis J, Shawler DL. Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer. ASCO Meeting Abstracts 2009. 27(15S):3013
31. Giaccone G BL, Nemunaitis J, et al. A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer. 2013 European Cancer Congress. Abstract LBA 2 Presented 28 September 2013
32. Eager R, Nemunaitis J. GM-CS F gene-Transduced tumor vaccines. Mol Ther 2005;12(1):18-27
33. Higano C, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer vs docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Proc Am Soc Clin Oncol. 2009 Genitourinary Cancer Symposium; Abstract # LBA150
34. Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Presented at the Genitourinary Cancers Symposium 2009. 83:Abstr 07
35. Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003;21(4): 624-30
36. Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004;96(4):326-31
37. Takahashi K, Shichijo S, Noguchi M, et al. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 1995;55(16):3478-82
38. Sienel W, Varwerk C, Linder A, et al. Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: Results of a multi-center study. Eur J Cardiothorac Surg 2004;25(1): 131-4
39. Gure AO, Chua R, Williamson B, et al. Cancer-Testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11(22):8055-62
40. Vansteenkiste J, Zielinski M, Linder A, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results. J Clin Oncol 2013;31(19):2396-403
41. GSK1572932A antigen-specific cancer immunotherapeutic as adjuvant therapy in patient with non-small cell lung cancer. Available from: Http://clinicaltrials.gov/ct2/ show/NCT00480025
42. Vlad AM, Kettel JC, Alajez NM, et al. MUC1 immunobiology: From discovery to clinical applications. Adv Immunol 2004;82: 249-93
43. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53(3):641-51
44. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-Associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998;4(1):43-9
45. Hirasawa Y, Kohno N, Yokoyama A, et al. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161(2 Pt 1):589-94
46. Hamanaka Y, Suehiro Y, Fukui M, et al. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003;103(1):97-100
47. Blixt O, Bueti D, Burford B, et al. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res 2011;13(2):R25
48. Sangha R, Butts C. L-BLP25: A peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007;13(15 Pt 2): S4652-4
49. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23(27):6674-81
50. Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (LBLP25): Phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011;137(9):1337-42
51. Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(1):59-68
52. Tecemotide following concurrent chemo-radiotherapy for non-small cell lung cancer (START2). Available from: Http:// clinicaltrials.gov/ct2/show/NCT02049151
53. Cancer vaccine study for stage III, unresectable, non-small cell lung cancer (NSCLC) in the Asian population (INSPIRE). Available from: Http:// clinicaltrials.gov/show/NCT01015443
54. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 2005;23(11):2556-68
55. Merlo V, Longo M, Novello S, Scagliotti GV. EGFR pathway in advanced non-small cell lung cancer. Front Biosci (Schol Ed) 2011;3:501-17
56. Rodriguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev 2010;12(1):17-23
57. Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008;26(9):1452-8
58. Vaccine therapy in treating patients with non-small cell lung cancer (NSCLC) Stages IIIB/IV. Available from: Http://clinicaltrials. gov/show/NCT00516685
59. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003;5(8):690-9
60. Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 2008;3(7):735-44
61. Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: A controlled phase 2B trial. Lancet Oncol 2011;12(12): 1125-33
62. Quoix EA, Nemunaitis JJ, Burzykowski T, et al. TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2012. 30(Suppl 15):TPS7610
63. Phase IIB/III Of TG4010 immunotherapy in patients with stage IV non-small cell lung cancer (TIME). Available from: Http:// clinicaltrials.gov/show/NCT01383148
64. Lopez PH, Schnaar RL. Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol 2009; 19(5):549-57
65. van Cruijsen H, Ruiz MG, van Der Valk P, et al. Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer 2009;9:180
66. Diaz Y, Gonzalez A, Lopez A, et al. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother 2009;58(7):1117-28
67. Segatori VI, Vazquez AM, Gomez DE, et al. Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Front Oncol 2012;2:160
68. Alfonso S, Diaz RM, de la Torre A, et al. 1E10 anti-idiotype vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients. Cancer Biol Ther 2007;6(12): 1847-52
69. Immunotherapy with racotumomab in advanced lung cancer. Available from: Http://clinicaltrials.gov/ct2/show/NCT01460472
70. Gail MH. A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. LCSG Protocol 771. Chest 1994; 106(6 Suppl):287s-92s
71. O'Brien ME, Saini A, Smith IE, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000;83(7): 853-7
72. Manegold C, van Zandwijk N, Szczesna A, et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2012;23(1):72-7
73. Hirsh V, Paz-Ares L, Boyer M, et al. Randomized phase III trial of paclitaxel/ carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011;29(19):2667-74
74. Spadaro M, Caorsi C, Ceruti P, et al. Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human Dendritic cells. FASEB J 2008;22(8):2747-57
75. Hayes TG, Digumarti R, Engelmeyer J, et al. Effect of oral talactoferrin (TLF) on levels of cytokines involved in the Th1-mediated immune response in clinical studies. ASCO Meeting Abstracts 2008. 26(15 Suppl):3080
76. Parikh PM, Vaid A, Advani SH, et al. Randomized, double-blind, placebo-controlled Phase II study of single-Agent oral talactoferrin in patients with locally advanced or metastatic non- small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 2011;29(31): 4129-36
77. Digumarti R, Wang Y, Raman G, et al. A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2011;6(6):1098-103
78. Ramalingam S, Crawford J, Chang A, et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol 2013; 24(11):2875-80
79. Kavanagh B, O'Brien S, Lee D, et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008;112(4):1175-83
80. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005;175(11):7746-54
81. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
82. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517-26
83. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase ii study. J Clin Oncol 2012;30(17):2046-54
84. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24(1):75-83
85. Trial in squamous non small cell lung cancer subjects comparing ipilimumab plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin. Available from: Http://clinicaltrials.gov/show/NCT01285609
86. Reck M, Lu H, Gribkoff G, et al. CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology. ASCO Meeting Abstracts 2013. 31(15 Suppl):TPS8117
87. Trial in extensive-disease small cell lung cancer (ED-SCLC) subjects comparing ipilimumab plus etoposide and platinum therapy to etoposide and platinum therapy alone. Available from: Http://clinicaltrials. gov/show/NCT01450761
88. Von Pawel J, Kim S-W, Spigel DR, et al. CA184-156: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/ platinum (EP) versus placebo plus EP in patients (Pts) with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC). ASCO Meeting Abstracts 2013. 31(15 Suppl):TPS7608
89. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704
90. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 2011;350:17-37
91. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54
92. Brahmer JR, Horn L, Antonia SJ, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): Overall survival and long-Term safety in a phase 1 trial. Abstract MO18.03 presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer. 27-30 October 2013. Sydney, Australia
93. Squibb B.-M. Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) (CheckMate 017). Available from: Http://clinicaltrials.gov/show/NCT01642004
94. Squibb B.-M. Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated metastatic non-squamous NSCLC (CheckMate 057). Available from: Http://clinicaltrials.gov/show/NCT01673867
95. Squibb B.-M. Study of Nivolumab (BMS-936558) in combination with gemcitabine/ cisplatin, pemetrexed/cisplatin, carboplatin/ paclitaxel, bevacizumab maintenance, erlotinib, ipilimumab or as monotherapy in subjects with stage IIIB/IV non-small cell lung cancer (NSCLC) (CheckMate 012). Available from: Http://clinicaltrials.gov/show/NCT01454102
96. Squibb B.-M. Study of Nivolumab (BMS-936558) in Subjects with advanced or metastatic squamous cell non-small cell lung cancer who have received at least two prior systemic regimens (CheckMate 063). Available from: Http://clinicaltrials.gov/show/NCT01721759
97. Sidney Kimmel comprehensive cancer center. Phase II anti-PD1 epigenetic priming study in NSCLC. (NA-00084192). Available from: Http://clinicaltrials.gov/show/NCT01928576 NLM identifier: NCT01928576
98. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369(2):134-44
99. Garon EB, Balmanoukian A, Hamid O, et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). Abstract MO18.02 presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer. 27-30 October 2013. Sydney, Australia
100. Sharp M. Study of two doses of MK-3475 versus docetaxel in previously-Treated participants with non-small cell lung cancer (MK-3475-010). Available from: Http://clinicaltrials.gov/show/NCT01905657
101. Sharp M. A Study of MK-3475 in combination with chemotherapy or immunotherapy in participants with lung cancer (MK-3475-021/KEYNOTE-021). Available from: Http://clinicaltrials.gov/show/NCT02039674
102. Grosso J, Inzunza D, Wu Q, et al. Programmed death-ligand 1 (PD-L1) expression in various tumor types. J Immunother Cancer 2013;1(Suppl 1):P53
103. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013;19(5):1021-34
104. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455-65
105. Nakanishi J, Wada Y, Matsumoto K, et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007;56(8):1173-82
106. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13(7):2151-7
107. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-Term follow-up. Cancer Res 2006; 66(7):3381-5
108. Mu CY, Huang JA, Chen Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28(3):682-8
109. Horn L HR, Spigel DR, et al. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1). Abstract MO18.01 presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer. 27-30 October 2013. Sydney, Australia
110. A phase 1b study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in combination with Tarceva in patients with non-small cell lung cancer. Available from: Http://clinicaltrials.gov/show/NCT02013219
111. A phase 2 study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in patients with PD-L1 positive locally advanced or metastatic non-small cell lung cancer - "FIR". Available from: Http:// clinicaltrials.gov/show/NCT01846416
112. A phase 2 study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in patients with PD-L1 positive locally advanced or metastatic non-small cell lung cancer - "BIRCH". Available from: Http:// clinicaltrials.gov/show/NCT02031458
113. A randomized phase 2 study of MPDL3280A (an Engineered Anti-PDL1 Antibody) compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy - "POPLAR". Available from: Http://clinicaltrials.gov/show/NCT01903993